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Abstract
Intrauterine devices (IUDs), long-acting and reversible contraceptives, induce a number of 
immunological and biochemical changes in the uterine environment that could affect endometrial 
cancer (EC) risk. We addressed this relationship through a pooled analysis of data collected in the 
Epidemiology of Endometrial Cancer Consortium. We combined individual-level data from 4 
cohort and 14 case-control studies, in total 8,801 EC cases and 15,357 controls. Using 
multivariable logistic regression, we estimated pooled odds ratios (pooled-ORs) and 95% 
confidence intervals (CIs) for EC risk associated with ever use, type of device, ages at first and 
last use, duration of use, and time since last use, stratified by study and adjusted for confounders. 
Ever use of IUDs was inversely related to EC risk (pooled-OR=0.81, 95% CI=0.74–0.90). 
Compared with never use, reduced risk of EC was observed for inert IUDs (pooled-OR=0.69, 95% 
CI=0.58–0.82), older age at first use (≥35 years pooled-OR=0.53, 95% CI=0.43–0.67), older age 
at last use (≥45 years pooled-OR=0.60, 95% CI=0.50–0.72), longer duration of use (≥10 years 
pooled-OR=0.61, 95% CI=0.52–0.71), and recent use (within 1 year of study entry pooled-
OR=0.39, 95% CI=0.30–0.49). Future studies are needed to assess the respective roles of detection 
biases and biologic effects related to foreign body responses in the endometrium, heavier bleeding 
(and increased clearance of carcinogenic cells), and localized hormonal changes.
Keywords
contraception; pooled analysis; endometrial neoplasm; etiology
INTRODUCTION
The intrauterine device (IUD) is a form of long-term reversible birth control initially 
marketed in the United States (US) in 1964 1. Several types of IUDs have been designed and 
sold over the years. Early IUDs were either inert devices made from plastic or stainless steel 
or progesterone-releasing devices 2. By the late 1980’s inert IUDs had been withdrawn from 
US markets because of safety concerns associated with a particular inert IUD, the Dalkon 
Shield 3. In the 1990’s, two IUDs were available in the US – a copper-bearing device 
(ParaGard) and a progesterone-releasing device (Progestasert); however, because of 
lingering concerns regarding the Dalkon Shield, the overall prevalence of IUD use dropped 
to its lowest frequency (0.5% of reproductive aged women) during this time period 3. Since 
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2001, ParaGard and Mirena (levonorgestrel-releasing IUD), both of which have pregnancy 
rates of less than 0.1 per 100 woman-years 4, have been available to US women. Compared 
with the US, IUDs are used extensively in European and Asian countries, particularly 
China 5. Of 150 million current IUD users worldwide, 100 million reside in China. In 
northern Europe, approximately 30% of contracepting women use the IUD 5.
Although the exact mechanism by which IUDs prevent pregnancy is unknown, and may 
vary by type of device, in the uterus, all IUDs elicit a local foreign body reaction 
characterized by increases in macrophages, neutrophils, and lymphocytes 6–8. This 
inflammatory environment has been suggested to affect pre-fertilization factors (inhibition 
of sperm migration, loss of sperm viability, altered cervical mucus, damage to ovum before 
fertilization) and post-fertilization factors (damage of the early embryo before it reaches the 
uterus, prevention of implantation) 9. Additionally, hormone-releasing devices suppress 
growth of the endometrial lining resulting in a thin endometrium 10.
IUDs may have long-term consequences on endometrial tissues given their direct placement 
in the uterine cavity and ability to evoke foreign body responses 11, 12. In 2007 and 2008, 
two meta-analyses examined the relationship between IUD use and endometrial cancer (EC) 
risk 1, 13. These analyses summarized ten epidemiologic studies 14–23 which together 
included 4,243 EC cases and 269,428 controls. These two meta-analyses reported odds 
ratios (ORs) of 0.54 1 [95% confidence interval (CI)=0.47–0.63] and 0.60 13 (95% CI=0.40–
0.70) associated with ever use of IUDs. Furthermore, Beining et al. 1 showed that longer 
duration of use and longer time since first or last use were associated with lower EC risk. 
While informative, these meta-analyses lacked in-depth explorations of specific types of 
IUDs, as only three published reports provided this information 17–19. Furthermore, analysis 
of quantitative metrics of IUD use (ages at first and last use, duration, time since last use) 
was limited by the small number of studies that reported these associations. Other issues that 
remain to be addressed include associations with EC tumor characteristics and potential 
effect modification by EC risk factors. Since the publication of these meta-analyses no 
additional studies have been published on the relationship between IUD use and EC risk.
Recent data from the National Survey of Family Growth indicate that the prevalence of IUD 
use is increasing in the US 24; therefore, further epidemiological investigations of long-term 
consequences are warranted. We sought to pool observational studies to examine 
relationships between IUD use and EC risk in the Epidemiology of Endometrial Cancer 
Consortium (E2C2).
METHODS
Study population
The E2C2, sponsored in part by the National Cancer Institute, combines data from cohort 
and case-control studies to study EC etiology 25. Studies that collected information on ever 
use of IUDs were eligible for the current analysis. For the cohort studies, a nested case-
control design was employed, with inclusion of up to four controls who were women with 
intact uteri and no EC diagnoses at the time of matching date, randomly selected and 
matched to the corresponding EC case on year of birth, date of cohort entry (within 6 
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months), and any additional matching criteria as appropriate in the individual study. 
Information on IUD use was differently collected in the cohort studies: ever use was 
assessed on the baseline questionnaire in three studies [Cancer Prevention Study II Nutrition 
Cohort (CPS-II) 26, Nurses’ Health Study (NHS) 27, and Swedish Women's Lifestyle and 
Health Study (WLHS) 28], current use was collected on the baseline, 1997, and 1999 
questionnaires in one study [Black Women’s Health Study (BWHS) 29], and information on 
ever use was collected at the time of a nested study interview obtained from a case-control 
study in two cohorts [California Teachers’ Study (CTS) 30 and New York University 
Women's Health Study (NYU) 31]. As such, the latter two studies are classified as case-
control studies. Cases in the cohort studies were identified through annual linkage to state or 
national cancer registries (WLHS and CTS), or by self-report on follow-up questionnaires 
and confirmed through medical record review, linkage to cancer registries, or the National 
Death Index (BWHS, CPS-II, NHS, and NYU).
In the case-control studies, hospital-based controls [Patient Epidemiologic Data System 
Study (PEDS) 32, Milano Endometrial Cancer Case Control Study 1 (MILANO 1) 33, 
Milano Endometrial Cancer Case Control Study 2 (MILANO 2) 34, and Switzerland 
Endometrial Cancer Study (SWEC) 35] or population-based controls were selected within 
each source population using random digit dialing [Connecticut Endometrial Cancer Study 
(CECS) 36, Estrogen, Diet, Genetics, and Endometrial Cancer Study (EDGE) 37, Fred 
Hutchinson Cancer Research Center Study 1 (FHCRC 1) - which also included Health Care 
Financing Administration (HCFA) controls and comparable controls from the Contraceptive 
and Reproductive Experiences Study (CARE) 38, Fred Hutchinson Cancer Research Center 
Study 2 (FHCRC 2) 39, Alberta Endometrial Cancer and Physical Activity Study 
(ALBERTA) 40, and US Case-Control Study (US) 41] or random selection from data 
registries of all citizens [Australian National Endometrial Cancer Study (ANECS) 42 and 
Shanghai Endometrial Cancer Study (SECS) 43]. Frequency matching was used in all case-
control studies except in the US study where individual 1:1 matching was employed. 
Frequency matching in FHCRC 2 was to the frequency of ovarian cancer cases in the same 
geographical area which has a similar age distribution as that for EC cases. For all case-
control studies, eligible controls were women with intact uteri and no histories of EC. 
Matching factors differed by study, but typically included age, race, and geographic region.
Women who were missing information for ever use of IUD (293 cases and 663 controls) 
were excluded from the analyses, leaving 8,801 EC cases and 15,357 control subjects. Three 
studies (US, SECS, MILANO 1) included in the previous meta-analyses 1, 13 contributed 
data to the E2C2 and therefore were included in our study. The remaining seven studies 
included in the previous meta-analyses did not contribute data to the E2C2 and were not 
included in our analysis. All studies were approved by the institutional review boards (IRBs) 
of their parent institutions, and informed consent was obtained from all participants.
Data collection
De-identified data from the participating studies were collected and harmonized at Memorial 
Sloan Kettering Cancer Center. Age at first IUD use was reported in 12 studies (ALBERTA, 
CTS, CECS, CPS-II, MILANO 1, MILANO 2, NYU, PEDS, SECS, SWEC, US, WLHS) 
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and age at last IUD use was reported in 8 studies (CECS, CPS-II, MILANO 1, MILANO 2, 
SECS, SWEC, US, WLHS). Duration of IUD use was either calculated as the time between 
dates of first and last IUD use or reported from questionnaire items asking about total length 
of use and was available in 13 studies (ALBERTA, ANECS, CTS, CECS, CPS-II, MILANO 
1, MILANO 2, NYU, PEDS, SECS, SWEC, US, WLHS). If multiple episodes of IUD use 
were reported, the duration is an accumulation across the time periods. Time since last IUD 
use was available in 8 studies (ALBERTA, CECS, CPS-II, MILANO 1, MILANO 2, SECS, 
SWEC, US). Seven studies provided information on the type of IUD used which included 
copper, inert, hormone-releasing, or use of combinations of devices (ANECS, CTS, FHCRC 
1, FHCRC 2, SECS, US, WLHS).
Available information on potential confounders differed by study. All studies provided 
information on age at diagnosis (cases), age at interview/reference date (controls), race, 
weight and height, ever use of menopausal hormone therapy (MHT), oral contraceptive 
(OC) use, and smoking. Some studies did not provide specific information on parity (NYU), 
age at last birth (ALBERTA, ANECS, CPS-II, CTS, EDGE, MILANO 1, MILANO 2, 
NYU, PEDS, SWEC, US), menopausal status (FHCRC 1, FHCRC 2), history of diabetes 
(WLHS, PEDS), or duration of OC use (ALBERTA, CECS, MILANO 1, MILANO 2, 
NYU, SWEC, WLHS). We considered number of pregnancies lasting at least 7 months as a 
surrogate for parity (NYU) and age at last pregnancy as a surrogate for age at last birth 
(ANECS, CTS, EDGE, PEDS, US). Missing values were coded as a separate category for 
each variable.
Case definitions
Women with incident, histologically confirmed diagnoses of EC were included as case 
patients in the current analysis. International Classification of Diseases for Oncology (ICD)-
O-3 morphology codes were provided by 12 studies (ALBERTA, ANECS, CTS, CECS, 
CPS-II, EDGE, FHCRC 1, FHCRC 2, NYU, PEDS, US, WLHS) while four studies (BWHS, 
NHS, SECS, SWEC) supplied summary histology variables for each case. Specific histology 
information was unavailable in the MILANO 1 and MILANO 2 studies; however, all cases 
were histologically confirmed. EC cases with the following ICD-O-3 histology codes or 
summary descriptions were included in the analysis: endometrioid (codes 8380–8383), 
adenocarcinoma tubular (codes 8210 and 8211), papillary adenocarcinoma (codes 8260, 
8262, and 8263), adenocarcinoma with squamous metaplasia (code 8570), mucinous 
adenocarcinoma (codes 8480 and 8481), adenocarcinoma not otherwise specified [(NOS) 
code 8140], clear cell (code 8310), serous (code 8441), papillary serous (codes 8460 and 
8461), squamous cell (codes 8050, 8070–8072), adenosquamous (code 8560), small-cell 
carcinoma (code 8041), and mixed-cell adenocarcinoma (code 8323). We classified these 
histologic subtypes into the broad Type I and Type II categories based on a previous study 
as described below 44.
Statistical methods
We employed two methods to analyze the association between IUD use and EC risk. First, 
we used a two-stage approach in which unconditional logistic regression was used to 
estimate study-specific ORs and 95% CIs for the association between ever use of IUDs and 
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EC risk adjusted for age at diagnosis or interview (continuous), race (White, Black, Asian, 
Other), body mass index [BMI (<25kg/m2, 25–30 kg/m2, ≥30 kg/m2), age at menarche (<11, 
11–12, 13–14, ≥15), duration of OC use (never use, <5, 5–9, ≥10 years, unknown duration), 
a combination of parity and age at last birth (nulliparous, 1–2 births and <25, 1–2 births and 
25–29, 1–2 births and 30–34, 1–2 births and ≥35, ≥3 births and <25, ≥3 births and 25–29, ≥3 
births and 30–34, ≥3 births and ≥35), menopausal status (premenopausal, postmenopausal), 
MHT use (never, ever), diabetes (never, ever), and smoking (never, former, current), when 
possible. These variables were identified as potential confounders given their known 
association with EC risk in this study population 44 and their association with IUD use 
among control subjects in the current analysis. The natural logarithms of the study-specific 
ORs were combined using the DerSimonian and Laird 45 random effects model that 
accounts for within- and between-study heterogeneity. The I2 test statistic was used as a 
measure of between-study heterogeneity 46. We conducted univariate random-effects meta-
regression to investigate features of the studies as sources of heterogeneity, including design 
(cohort vs. case-control), geography (North America vs. Europe, China, Australia), year of 
exposure ascertainment (<1990, 1990–2000, ≥2001), and prevalence of IUD use (<10%, 10–
19%, 20–49%, ≥50%) 47. We also conducted a sensitivity analysis excluding each study and 
re-estimating the meta-OR and I2 to determine whether any studies disproportionately 
contributed to our estimates.
Next, we combined the individual-level data from each study into one dataset and performed 
logistic regression analyses stratified by study to determine pooled-ORs and 95% CIs. 
Associations of EC risk with IUD use (never, ever), IUD type (copper, inert, hormone-
releasing, combination, unknown), age at first use (<25, 25–29, 30–34, or ≥ 35 years), age at 
last use (<30, 30–39, 40–44, or ≥ 45 years), duration of use (<1, 1–4, 5–9, or ≥10 years), and 
time since last use (within 1 year of study entry, 1–4, 5–9, or ≥10 years) were examined. In 
the analyses of ages at first and last use, duration, and time since last use, we first included 
all studies that provided information on the pertinent variable. Subsequently, we re-ran the 
analyses restricted to case-control studies as these variables were assessed near the time of 
case diagnosis or control selection which differs from the assessment in the cohort studies, 
where the exposure was ascertained at baseline. Tests for linear trend were performed 
among IUD users (i.e., excluding never users) by entering the ordinal values representing 
the categories for each quantitative IUD-related variable. We also explored relationships 
between the quantitative IUD measures (ages at first and last use, duration, time since last 
use) according to type of device used.
We examined whether the association of EC risk with IUD use varied over strata of other 
EC risk factors, including age at diagnosis/interview, parity, BMI, menopausal status, OC 
use, MHT use, smoking status, and diabetes. Tests for effect modification were done using 
the likelihood-ratio procedure, comparing models with and without the interaction term 
between IUD use and the covariate of interest. Women with missing values for potential 
effect modifier variables were excluded. We also examined the association between IUD use 
and tumor characteristics (histological subtype and stage) using polytomous logistic 
regression models. Other than endometrioid tumors, we had a limited number of histological 
subtypes in our study population, which precluded analyses of specific histologies. Instead, 
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we broadly classified tumors by histology as Type I (endometrioid, adenocarcinoma NOS, 
adenocarcinoma with squamous metaplasia, and adenosquamous) or Type II (serous, 
papillary serous, and mixed-cell adenocarcinoma) 44. The Surveillance, Epidemiology, and 
End Results (SEER) classification of stage (local, regional, distant) was available in 6 
studies (BWHS, CTS, CPS-II, EDGE, FHCRC, PEDS) while the International Federation of 
Gynecology and Obstetrics (FIGO) stage (1988 criteria) was available in 6 studies 
(ALBERTA, ANECS, NYU, SECS, US, WLHS). We consolidated FIGO stage into three 
categories to recapitulate the SEER summary stage groupings (Localized=FIGO stages 1 
and 2; Regional=FIGO stage 3; Distant=FIGO stage IV). Differences in ORs between case 
groups were quantified using case-only models. Analyses were performed using SAS 9.3 
(SAS Institute Inc., Cary, NC) and STATA 11.2 (StataCorp LP, College Station, TX).
RESULTS
Table 1 describes the characteristics of the four cohort and 14 case-control studies that 
contributed to the analysis. The prevalence of IUD use among controls ranged between 1.7% 
(BWHS) and 56.1% (WLHS). The time periods in which IUD use was ascertained also 
varied considerably, spanning from 1980 (NHS) to 2009 (CECS). Characteristics of the 
controls according to IUD use are shown in Supplemental Table 1. A total of 2,288 controls 
(14.9%) reported ever use of IUDs and these women were more likely to be younger at 
study entry, Asian, normal-weight, and older at menarche compared with non-IUD users. 
While IUD users were more likely to be parous than non-users (93.9% vs. 85.8%), IUD 
users tended to have a lower number of live births compared to non-IUD users. IUD users 
were more likely to be younger at last birth, premenopausal at study entry, use OCs for short 
durations, and never smoke relative to non-users.
The study-specific ORs and 95% CIs for EC risk associated with ever use of IUDs are 
displayed in Figure 1. Estimates of the association were significantly heterogeneous between 
studies (meta-OR=0.83, 95% CI=0.72–0.96, I2=68.6%, p<0.0001). The association was not 
heterogeneous among the cohort studies (OR=0.86, 95% CI=0.67–1.10, I2=0%, p=0.87) but 
was heterogeneous among the case-control studies (OR=0.82, 95% CI=0.69–0.98, 
I2=75.8%, p<0.0001); however, study design was not a significant source of between-study 
heterogeneity in the univariate meta-regression (p=0.79). We also performed univariate 
meta-regression analyses among the case-control studies and found no significant 
heterogeneity by geography (p=0.84), year of exposure ascertainment (p=0.59), or 
prevalence of IUD use (p=0.50, data not tabled). In sensitivity analyses where we excluded 
each study in turn and re-analyzed the estimates, one study contributed to the heterogeneous 
effect estimates (SECS: OR=0.57, 95% CI=0.46–0.69). After excluding the SECS, the meta-
OR was 0.83 (95% CI=0.74–0.94) and the between-study heterogeneity improved 
(I2=42.6%, p=0.04). In subsequent analyses that combined data across the 18 studies, we 
stratified by study to account for between-study heterogeneity and additionally ran 
sensitivity analyses excluding SECS.
Table 2 presents associations between IUD characteristics and EC risk in the pooled dataset. 
The pooled-OR of 0.81 (95% CI=0.74–0.90) for ever versus never use of IUDs was similar 
to the meta-OR. The inverse association between IUD use and EC risk was strongest among 
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users of inert IUDs (pooled-OR=0.69, 95% CI=0.58–0.82), with weaker associations being 
observed among users of copper IUDs (pooled-OR=0.89, 95% CI=0.66–1.21), hormone-
releasing IUDs (pooled-OR=0.97, 95% CI=0.44–2.14), or use of a combination of IUDs 
(pooled-OR=0.88, 95% CI=0.65–1.19). Compared with never use, older age at first use (≥35 
years pooled-OR=0.53, 95% CI=0.43–0.67, p-trend =0.17), older age at last use (≥ 45 years 
pooled-OR=0.60, 95% CI=0.50–0.72, p-trend =0.01), longer duration (≥10 years pooled-
OR=0.61, 95% CI=0.52–0.71, p-trend=0.16), and recent use (within 1 year of study entry 
pooled-OR=0.39, 95% CI=0.30–0.49) were inversely related to EC risk.
We re-analyzed the associations between the quantitative IUD variables (ages at first and 
last use, duration, time since last use) and EC risk in models restricted to case-control 
studies (Supplemental Table 2). We did not observe major differences in these analyses 
compared with the full model; however, the estimates in the case-control only analyses 
typically showed a greater reduction in EC risk compared with estimates from the models 
including all studies. Further, all analyses shown in Table 2 were re-analyzed excluding the 
major outlier, SECS (Supplemental Table 3). Overall, the IUD variables showed similar 
magnitudes of association with EC risk compared with the full models, but some 
associations were attenuated.
Table 3 presents associations between EC risk and quantitative IUD metrics by device type. 
Among the inert IUD users, older ages at first and last use, longer duration, and recent use 
were inversely related to EC risk – the magnitudes of associations were similar to the 
associations observed in the full cohort. Among copper IUD users, none of the associations 
reached statistical significance. We did not assess associations among hormone-releasing 
IUD users because of small numbers of exposed women.
Potential effect modification of the relationship between IUD use and EC risk by established 
EC risk factors using a common referent group is shown in Table 4. Parity (p-
interaction=0.001), menopausal status (p-interaction=0.006), and MHT use (p-
interaction=0.008) were significant effect modifiers. Compared to nulliparous women who 
never used IUDS, nulliparous women who ever used IUDs had a reduced risk of EC 
(pooled-OR=0.48, 95%CI=0.34–0.68) that was more pronounced than EC risks among 
parous never IUD users (pooled-OR=0.74, 95% CI=0.65–0.85) or parous ever IUD users 
(pooled-OR=0.63, 95% CI=0.54–0.74). Postmenopausal women who ever used IUDs had a 
reduced EC risk (pooled-OR=0.72, 95% CI=0.62–0.83) compared to premenopausal never 
IUD users. For MHT use, we changed the referent category to MHT users who never used 
an IUD to clearly demonstrate patterns of association. Of note is the finding that among 
MHT users, IUD use reduced the risk of EC from 1.00 to 0.60 (95% CI=0.50–0.72). The 
association between IUD use and EC risk was not significantly modified by age at diagnosis, 
BMI, OC use, smoking status, or diabetes.
Ever use of IUDs was inversely associated with Type I (pooled-OR=0.87, 95% CI=0.79–
0.95) but not Type II EC subtypes (pooled-OR=1.05, 95% CI=0.81–1.36) (data not tabled). 
The p-value for tumor heterogeneity indicated no difference in the associations (p-
heterogeneity=0.98). The inverse association with ever use of IUDs was more strongly 
associated with distant stage tumors (pooled-OR=0.45, 95% CI=0.24–0.86) than local stage 
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tumors (pooled-OR=0.90, 95% CI=0.81–1.00) but the observed differences were not 
statistically significant (p-heterogeneity=0.12) (data not tabled).
DISCUSSION
The present pooled analysis of individual level data from 18 epidemiologic studies is the 
largest and most comprehensive investigation of IUDs and EC risk to date. Ever use of IUDs 
was inversely associated with EC risk, independent of known risk factors. Analysis of 
specific characteristics of IUD use showed that inert IUDs, older ages at first and last use, 
and recent use were significantly related to lower EC risk.
Our findings agree with the majority of previous studies. However, our pooled-OR of 0.81 is 
a more modest estimate of the association compared with previous studies, which reported 
ORs between 0.37 and 0.61 15, 19–23. Three previous studies examined specific types of 
IUDs 17–19, none of which demonstrated significant associations with any particular device, 
probably due to small numbers of cases and controls exposed to specific IUD types. We 
observed a significant association with inert IUDs, which was the most prevalent IUD type 
used in our study population. This observation likely reflects the fact that inert IUDs were 
most commonly used in the 1980s which provided a suitable latency period for ECs to 
occur. Although not statistically significant, the OR for copper IUDs suggested an inverse 
relationship. With only 21 cases and 12 controls exposed to hormone-releasing IUDs, we 
could not generate meaningful estimates for this device. Because the hormone-releasing type 
of IUD is now the most commonly used IUD in the US, future epidemiologic studies are 
needed to investigate a possible association with this type of IUD. Data from a recent 
Finnish study showed that the levonorgestrel-releasing intrauterine system is inversely 
associated with EC risk 48.
No previous individual study has demonstrated a dose-response association with quantitative 
characteristics of IUD use 15, 17–19, 22. A meta-analysis 1 summarizing these individual 
studies observed a lower EC risk with increasing duration of use, longer time since first use, 
and longer time since last use. We observed lower EC risks with longer duration of use, both 
in the overall study population and among inert IUD users. Our findings that older age at 
first use and recent use are inversely related to EC risk are not in line with the meta-analysis 
findings, possibly suggesting that the underlying mechanism of IUD protection is complex. 
Disentangling which quantitative IUD characteristics specifically drive the relationship is 
needed, but difficult given the high correlation between these variables. Even in our study 
including a large number of cases and controls, we could only explore the contribution of 
two quantitative IUD metrics at one time in a given model, and these models were restricted 
to IUD users. Future studies conducted on this topic that are subsequently combined with 
existing data may be able to shed light on these complex relationships.
Sporadic endometrial carcinogenesis is believed related to risk factors that increase estrogen 
exposure relative to progesterone 49. Imbalances in these hormones lead to increases in 
mitotic activity of endometrial cells with increased opportunities for DNA replication errors 
and subsequent neoplastic transformation 50. As such, the possibility that IUDs protect the 
endometrium by changing the balance of hormone receptors in the uterus is an attractive 
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hypothesis, but clinical studies with similar sample sizes have provided inconsistent 
evidence. For example, following insertion of copper IUDs, some have shown decreases in 
progesterone receptor (PR) but not estrogen receptor (ER) 51, 52, no changes in ER or PR 53, 
or decreases in ER but not PR 54. Only the last study is consistent with a mechanism that 
would decrease EC risk through lower estrogen sensitivity relative to progesterone. 
Hormone-releasing devices, which deliver levonorgestrel directly to the endometrial lining, 
have been shown to down-regulate ER and PR in some studies 55–58, while others report 
down-regulation of PR only 59, 60. Again, these studies are inconsistent with a mechanism 
that would decrease EC risk through lower ER activity compared to PR. Moreover, the 
literature provides conflicting evidence regarding variations in serum ovarian steroid-
hormone levels between IUD users and non-users 60–64. At this time it is unclear whether 
IUDs, particularly inert IUDs, lower EC risk through hormonal mechanisms.
Another mechanism that may account for lower EC risk among IUD users is through 
increased decidual loss, which transiently increases following insertion of all types of 
IUDs 65–70. This process may allow for more complete shedding of the endometrial lining, 
with subsequent removal of premalignant or hyperplastic endometrial cells. Along the same 
lines, the foreign body response elicited by IUDs may lead to the elimination of pre-
malignant endometrial cells. Although inflammation is thought to promote 
carcinogenesis 71, and has even been offered as a hypothesis to explain etiologic factors and 
EC risk 72, we suspect that the timing of the IUD-elicited foreign body response relative to 
the stage of carcinogenesis is central to this relationship. We hypothesize that the 
inflammatory milieu stimulated by IUDs offers protection to women who may be more 
likely to have premalignant or hyperplastic changes (i.e. ages 40–50) compared with 
younger women with no evidence of these changes. Our finding of an inverse trend with 
increasing age at last IUD use is consistent with this hypothesis. The role of these potential 
mechanisms should be considered in future studies.
In our analysis, parity, menopausal status, and MHT use modified the relationship between 
IUD use and EC risk. The odds of EC range between 1.5 and 3.5 for nulliparous compared 
with parous women 73–75, a finding we noted in the current study. We observed that 
nulliparous women who ever used an IUD had a 52% lower risk of EC compared with 
nulliparous women who never used an IUD. A potential shared mechanism by which parity 
and IUD use may lower EC risk is through shedding of precancerous cells in the endometrial 
lining of the uterus. IUDs may afford greater protection to nulliparous women who lack such 
a mechanism compared to parous women. Among postmenopausal women, we observed a 
28% reduced EC risk with IUD use whereas no association was observed for premenopausal 
women. Younger EC cases are more likely to have a genetic predisposition to the disease 76 
which may not be reduced by IUD use, whereas postmenopausal EC is more likely to 
represent a sporadic disease influenced by modifiable risk factors. Finally, we observed that 
IUD use lowered EC risk among MHT users, which may indicate that IUDs exert an anti-
hormonal influence; however, these findings should be interpreted cautiously as the type and 
duration of MHT use were unavailable in this study.
The major strength of this study is the large sample size, which offered more statistical 
power than in any of the individual published studies which included between 85–1,204 EC 
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cases. Further strengths include uniform adjustment for confounders and use of consistent 
categories for the IUD variables across studies, which was a limitation of the previous meta-
analysis 1. However, our study had limitations as well. Although we included a large 
number of studies in our analysis, very few studies collected detailed IUD information, 
limiting our assessment of IUD type, ages at first and last use, duration, and time since last 
use. Furthermore, although we adjusted for factors that differed between IUD users and non-
users, residual confounding by other factors for which we did not have information could 
have occurred, including postmenopausal hormone use and contra-indications for IUD use. 
Not all studies included in our analyses have detailed information on the usage of 
postmenopausal hormones among cases and controls to allow an overall evaluation on 
whether hormone use might confound the observed results. To address the question of 
potential confounding by hormone use, we analyzed the data from the FHCRC case-control 
studies, which have detailed information on the type, dosage, duration and recency of 
hormone use among the study participants. The results showed that the use of estrogen-alone 
or estrogen plus progestin for less than 10 days per month did not confound the association 
between IUD use and EC risk, nor did inclusion of duration and recency. So, at least based 
on the FHCRC studies, postmenopausal hormone use does not seem to be a confounder. 
Regarding contra-indications for IUD use as a potential confounder, women with conditions 
that result in irregular bleeding (i.e. fibroids, polycystic ovary syndrome) may be 
discouraged from using IUDs, but these women may be at higher risk of developing EC. 
This would cause a downward bias of the OR for IUD use.
Another potential limitation of our study is that we observed significant heterogeneity in the 
meta-OR among the case-control studies, driven in large part by the SECS. While the 
estimate obtained in the SECS is stronger than any of the other studies, the association was 
in the same direction. In this large case-control study, a lower prevalence of other EC risk 
factors, namely, obesity, coupled with a high prevalence of IUD use may have driven the 
lower risk associated with IUDs. Finally, our finding that recent IUD use lowers EC risk 
suggests potential surveillance bias, which could arise if IUD users have more interactions 
with healthcare providers compared with non-users and were more often treated for 
premalignant conditions. We could not directly test this in our study population; however, 
studies that prospectively evaluate the risk of developing endometrial hyperplasia would be 
well-suited to analyze this relationship.
In summary, our pooled analysis provides evidence that IUD use is associated with a lower 
risk of developing EC. Future studies incorporating endometrial tissue samples collected 
before and after IUD insertion would be useful in describing the biological mechanisms 
underlying the observed inverse association. Additionally, future studies will need to include 
a larger number of hormone-releasing device users to adequately address the long-term 
effects of the devices in primary use today. A better understanding of the relationship 
between IUD use and EC risk may guide healthcare recommendations for the use of IUDs 
beyond family planning indications.
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Novelty and Impact Statement
Worldwide, intrauterine devices (IUDs) are an increasingly common contraceptive. In the 
uterus, IUDs elicit immunological and biochemical changes that could have implications 
for cancer risk. We examined the association between IUDs and endometrial cancer (EC) 
risk. Inert devices, older ages at first and last use, longer duration, and recent use were 
inversely associated with EC risk. Our results may be useful to health care providers that 
counsel patients regarding benefits and risks of IUDs.
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Figure 1. 
Forest plot of intrauterine device use and endometrial cancer risk
Footnote: One study (MILANO 2) was not included in the forest plot as ORs and 95% CIs 
were not estimable due to zero exposed cases.
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Table 2
Odds ratios (ORs) and 95% confidence intervals (CIs) of IUD characteristics and endometrial cancer risk
Cases Controls
OR (95% CI)1
n (%)
IUD use
  Never user 7368 (83.7) 13069 (85.1) Ref
  Ever user 1433 (16.3) 2288 (14.9) 0.81 (0.74, 0.90)
IUD type2
  Never user 2995 (73.7) 2883 (66.8) Ref
  Copper 108 (2.7) 405 (9.4) 0.89 (0.66, 1.21)
  Inert 385 (9.5) 521 (12.1) 0.69 (0.58, 0.82)
  Hormone-releasing 21 (0.5) 12 (0.3) 0.97 (0.44, 2.14)
  Combination 86 (2.1) 140 (3.2) 0.88 (0.65, 1.19)
  pWald 0.005
Age at first IUD use3
  Never user 4777 (84.0) 9642 (84.1) Ref
  <25 125 (2.2) 279 (2.4) 0.84 (0.66, 1.06)
  25–29 321 (5.6) 588 (5.1) 0.74 (0.63, 0.87)
  30–34 325 (5.7) 563 (4.9) 0.72 (0.61, 0.86)
  ≥35 131 (2.3) 361 (3.1) 0.53 (0.43, 0.67)
  ptrend4 0.17
Age at last IUD use5
  Never user 3394 (83.0) 7504 (74.5) Ref
  <30 85 (2.1) 203 (2.3) 0.73 (0.55, 0.97)
  30–39 206 (5.3) 383 (4.3) 0.92 (0.75, 1.13)
  40–44 101 (2.5) 255 (2.9) 0.58 (0.44, 0.75)
  ≥45 276 (6.7) 485 (5.5) 0.60 (0.50, 0.72)
  ptrend4 0.01
Duration of use (years)6
  Never user 5403 (81.6) 9412 (82.7) Ref
  < 1 260 (3.9) 399 (3.5) 0.86 (0.68, 1.09)
  1–4 342 (5.2) 565 (5.0) 0.80 (0.68, 0.94)
  5–9 176 (2.7) 262 (2.3) 0.99 (0.80, 1.24)
  ≥10 400 (6.0) 694 (6.1) 0.61 (0.52, 0.71)
  ptrend4 0.16
Time since last IUD use (years)7
  Never user 3738 (83.6) 7993 (86.3) Ref
  Within 1 year of study entry 157 (3.5) 337 (3.6) 0.39 (0.30, 0.49)
Int J Cancer. Author manuscript; available in PMC 2016 March 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Felix et al. Page 22
Cases Controls
OR (95% CI)1
n (%)
  1–4 108 (2.4) 136 (1.5) 0.83 (0.62, 1.11)
  5–9 87 (1.9) 117 (1.3) 0.85 (0.62, 1.17)
  ≥10 365 (8.2) 645 (7.0) 0.78 (0.67, 0.91)
  ptrend4 <0.0001
1Adjusted for age (continuous), race (White, Black, Asian, Other), BMI (< 25kg/m2, 25–30 kg/m2, ≥30 kg/m2), age at menarche (<11, 11–12, 13–
14, ≥15), duration of oral contraceptive use (never, <5, 5–9, ≥10 years), parity/age at last birth (nulliparous, 1–2 births and <25, 1–2 births and 25–
29, 1–2 births and 30–34, 1–2 births and ≥35, ≥3 births and <25, ≥3 births and 25–29, ≥3 births and 30–34, ≥3 births and ≥35), menopausal status 
(premenopausal, postmenopausal), any menopausal hormone use (never, ever), smoking status (never, former, current), and stratified by study 
2Available in ANECS, CTS, FHCRC 1, FHCRC 2, SECS, US, WLHS
3Available in ALBERTA, CTS, CECS, CPS-II, MILANO 1, MILANO 2, NYU, PEDS, SECS, SWEC, US, WLHS
4p-value for trend was calculated using the Wald test for the ordinal variable based on the categories shown excluding never IUD users
5Available in CECS, CPS-II, MILANO 1, MILANO 2, SECS, SWEC, US, WLHS
6Available in ALBERTA, ANCES, CTS, CECS, CPS-II, MILANO 1, MILANO 2, NYU, PEDS, SECS, SWEC, US, WLHS
7Available in ALBERTA, CECS, CPS-II, MILANO 1, MILANO 2, SECS, SWEC, US
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